Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
Thomas G Martin(University of California, San Francisco), Cesar Rodriguez(Wake Forest University), Ajay K. Nooka(Emory University), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Clarissa Uhlar(University of Pennsylvania), Margaret Doyle(Janssen (Ireland)), Weili Sun(Janssen (Belgium)), Lixia Pei(Nanjing University of Chinese Medicine), Ming Qi(University of Cape Town), Jennifer Smit(Janssen (United States))
Cited by 66
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k